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The treatment response of alopecia areata (AA) is often unpredictable. The aim of this study was to report
the efﬁcacy of an excimer lamp in treating AA. Seventeen AA patients were included. The overall
response rate was 41.1%, and the satisfactory response rate was 29.4%. In patients with severe AA, the
response rate was 50%. The therapeutic effect of the excimer lamp was evident by internal control. The
onset of improvement occurred after 2 months, and only mild side effects were noted. Our results
suggest that the 308-nm excimer lamp is a safe alternative treatment for AA, including those with
severe AA.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Alopecia areata (AA) is a nonscarring hair loss disease that is
generally regarded as an autoimmune disorder mediated by T
lymphocytes.1,2 In patients with limited involvement, AA is ex-
pected to be self-limited and spontaneous recovery is possible.
However, in patients with higher severity, the treatment of AA is
usually frustrating for both the patients and doctors because of the
lack of deﬁnite responsiveness and high recurrence rate.3 The use of
corticosteroids through a topical, intralesional, or systemic route is
currently the mainstay of treatment. However, long-term usage of
corticosteroids is limited by several well-documented side effects.
An excimer light of 308-nm wavelength was used to treat viti-
ligo and psoriasis due to its suppressive effects on T lymphocytes,4
and was reported to elicit rapid responses in fewer treatments than
narrow-band UV-B light.4,5 The promising effect of the excimer
light in treating AA had also been shown in a few case reports or
small case-series.6,7 In this study, we retrospectively reviewed our
cases and aimed to show the efﬁcacy of excimer light therapy and to
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Patients
Patients with AA who were treated with a 308-nm excimer lamp
between 2011 and 2014 at the Department of Dermatology, Na-
tional Cheng Kung University Hospital, Tainan, Taiwan were
retrospectively recruited. Their medical records and serial clinical
photos were reviewed. The excimer lamp was not used as a routine
ﬁrst-line therapy for AA in our department but rather an alternative
choice for refractory cases. The ﬁrst-line therapy was intralesional
corticosteroid injection or topical potent corticosteroid application
with or without topical minoxidil for almost all patients with AA.
Oral or intravenous corticosteroid pulse therapy was used in pa-
tients with severe and acute AA. Immunomodulatory agents such
as sulfasalazine were used in severe and chronic patients. If these
treatments failed to yield any positive effect within 3 months, the
excimer lamp would then be used in these patients.Treatment protocol
The VTRAC™ Excimer Lamp (spot size 18.9 cm2, power density
150mW/cm2; PhotoMedex, Inc., Horsham, PA, USA)was used as the
light source in this study. The hair loss area on the scalp was treated
with an excimer lamp two to three times each week. The initial
irradiation dosage was either 50 mJ/cm2 or 100 mJ/cm2 dependingier Taiwan LLC. All rights reserved.
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50 mJ/cm2 every week until the occurrence of intolerable painful
erythema or desquamation. In some patients, prior medical treat-
ments were not discontinued in order to maintain the existing
therapeutic effect. Application of excimer light on only half of the
lesions and the other half left untreated as an internal control was
performed in ﬁve patients. Those patients who did not receive
excimer light treatment for a sufﬁcient period longer than 8 weeks
were excluded.
Clinical parameters and evaluation protocol
The evaluation of the extent of hair loss was performed by two
independent dermatologists by reviewing serial clinical photo-
graphs based on the Alopecia Areata Investigational Assessment
Guidelines.8 The severity of hair loss at the time that excimer light
treatment was initiated was classiﬁed into mild (hair loss < 50% of
total scalp) and severe (hair loss  50%). The response rate was
deﬁned as the percentage of patients with regrowth of hair to any
extent, and a “satisfactory response rate” was deﬁned as the per-
centage of patients with hair regrowth of more than 50% of the hair
loss areas. Recurrence was deﬁned as worsening of hair loss to any
extent after receiving excimer light treatment in the responders.
To analyze the difference in response rates between subgroups
of patients, the Chi-square test was used and p < 0.05 was regarded
as statistically signiﬁcant.
Results
There were 17 patients recruited in this study, including six males
(35.3%) and 11 females (64.7%) (Table 1). The mean age was 34.6
years (range 10e64 years). Eight (47.1%) patients had a history of AA
for more than 1 year. The initial severity of AA in these patients was
mild (<50% hair loss) in seven patients (41.2%) and severe (50%) in
10 patients (58.8%), with ﬁve patients (29.4%) having complete loss
of scalp hair during initial stages. The patients received a median of
37 sessions (range 14e118 sessions) of excimer light treatment. The
median of the accumulated dose in a patient was 8.05 J/cm2 (range
3.4e75.6 J/cm2) and the median of the maximal dose in a single
session in a patient was 0.45 J/cm2 (range 0.15e0.8 J/cm2).
The overall response rate for the excimer light in treating AAwas
41.2%, with ﬁve patients (29.4%) having more than 50% regrowth of
lesional areas (satisfactory response) and two patients (11.7%) hav-
ing less than 50% regrowth of lesional areas. However, 10 patients
(58.8%) had no hair regrowth or aggravated extent of hair loss. In the
ﬁve patients with alopecia totalis or alopecia universalis, the
response ratewas 60%. In theﬁve patients that received treatment ofTable 1 Response to excimer light treatment in 17 patients and analysis of factors
related to favorable outcomes.
Patient subgroup Response rate (%) pa
Overall (n ¼ 17) 41.1
Age, y
40 (n ¼ 11) 45.5 >0.05
>40 (n ¼ 6) 33.3
Sex
Male (n ¼ 6) 50.0 >0.05
Female (n ¼ 11) 36.4
Initial severity
Hair loss < 50% (n ¼ 7) 28.6 >0.05
Hair loss  50% (n ¼ 10) 50.0
AT or AU (n ¼ 5) 60.0
AA history duration
1 y (n ¼ 9) 75.0 <0.05
>1 y (n ¼ 8) 11.1
AA ¼ alopecia areata; AT ¼ alopecia totalis; AU ¼ alopecia universalis.
a Comparison of response rates between the subgroups.half the lesions (the other half left untreated as the control site),
three patients (60%) showed a signiﬁcant difference between
treated and untreated areas. Among the ﬁve responders in whom
the timing of improvement was available from medical charts or
photo records, improvement of hair loss was ﬁrst noted after 18
sessions (median, range 7e20) of excimer light treatment, which
took approximately 2 months (median, range 1.5e4 months).
Side effects were observed in seven patients (41.2%) including
painful erythema in three, desquamation in three, and pruritus in
three. Some patients had more than one side effect while asymp-
tomatic erythemawas excluded as a side effect. All of these patients
had their side effects resolved after temporarily discontinuing the
excimer light treatment for 1 week, and were resumed with a
reduced dose. Recurrence of AA after receiving excimer light
treatment was noted in one (25%) out of four responders in whom
the follow-up period was longer than 6 months.
To analyze the factors that were associated with favorable out-
comes of excimer light treatment, the patients were classiﬁed into
subgroups and the response rates were compared (Table 1). There
was no signiﬁcant difference in the response rates in different age,
sex, or severity groups. However, patients with shorter AA dura-
tions (1 year or shorter, n ¼ 9) had a more favorable response to
excimer light treatment than patients with longer AA durations
(longer than 1 year, n ¼ 8; response rate 75.0% vs. 11.1%, p < 0.05).
Discussion
The overall response rate of excimer lamp treatment in treating AA
was 41.2% and a satisfactory response was achieved in 29.4% of the
patients. The response rate was lower compared to previous
studies, probably due to the selection of refractory cases in our
study (Table 2). To date, our study included the highest number of
cases among all the series. It is noteworthy that in patients with
higher severity (>50% hair loss), the overall response rate was 50%
and the satisfactory response rate was 30%, suggesting that the
excimer lamp could be considered as an alternative treatment even
in patients with higher severity of AA. In our department, wewould
recommend patients with AA to receive intralesional corticosteroid
injection or topical potent corticosteroid as the ﬁrst-line treatment.
For patients with extensive (>50%) hair loss that lasted less than 2
years, we would also recommend corticosteroid pulse therapy.9 If
these therapies failed to yield positive effects after 3 months,
excimer light therapy would be offered as one of the treatment
choices.
The positive effect of excimer light in treating AA was demon-
strated by the strategy of comparing the treated area with the
untreated lesions (internal control) in the same individual. We
found that three (60%) out of ﬁve patients that received treatment
of half the lesions (internal control) showed a signiﬁcant difference
between treated and untreated areas.
Photochemotherapy (PUVA) or narrow-band UV-B have been
utilized to treat AA because of the immunosuppressive effects.9
Similarly, the 308-nm excimer light acts on T lymphocytes, kera-
tinocytes, and dendritic cells and provokes their apoptosis.7 The
advantage of an excimer light over another type of UV light is the
small irradiance area, which targets lesions speciﬁcally and avoids
damage to normal skin. Unlike photochemotherapy, the excimer
light does not require a photosensitizing agent and it requires less
frequent treatment sessions than narrow-band (NB)-UVB.10,11
However, due to the potential risk of carcinogenesis, excimer
light therapy needs to be used with caution and long-term use
should be avoided.
There were limitations in this study including selection bias due
to the retrospective nature, and a small sample size, which might
lead to difﬁculty in concluding the therapeutic effects. The
Table 2 Summary of the published data on the effect of an excimer light in treating AA.
Author (year) Case numbers AA severity Response
rate (%)
Satisfactory response
ratea (%)
Treatment frequency/number of sessions
Zakaria et al (2004)6 9 Overall 55.6 55.6 Every 2 weeks/12e24 sessions
AA (n ¼ 5) 100.0 100.0
AU/AT (n ¼ 4) 0.0 0.0
Akiko et al (2013)12 16 Overall 87.5 62.5 Every 2 weeks/3e40 sessions
Single AA (n ¼ 7) 85.7 57.1
Multiple AA (n ¼ 9) 88.9 66.7
Current study 17 Overall 41.2 29.4 2e3 sessions weekly/14e118 sessions
AA < 50% (n ¼ 7) 28.6 28.6
AA  50% (n ¼ 10) 50.0 30.0
AT/AU 60.0 40.0
AA ¼ alopecia areata; AT ¼ alopecia totalis; AU ¼ alopecia universalis.
a Response rate with hair growth 50%.
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tation of therapeutic response difﬁcult.
Our study suggests that a 308-nm excimer lamp is a safe and
effective alternative treatment, either as an adjunctive or main
modality, even in patients with severe and recalcitrant AA.
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